Merck ($MRK) removes 'fast-acting relief' from allergy ads

After competitor complaints and U.K. regulatory action, Merck ($MRK) will remove its "fast-acting relief" claims from its Clarityn--sold in the U.S. as Claritin--allergy pills. Johnson & Johnson complained to the U.K. Medicines and Healthcare products Regulatory Agency about Merck's claims that its pill provided fast-acting relief from hay fever symptoms, saying there wasn't enough evidence to back the statement. In November, the agency sided with J&J, saying the fast-acting moniker should only be used when relief occurs within 30 minutes, which Merck could not definitively prove.

The MHRA also said that any product using Clarityn's active ingredient, loratadine, should remove similar claims.

- read the Dow Jones piece

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.